The US pharmaceutical company Moderna said on Wednesday that preliminary research it has done indicates that its COVID-19 vaccine is safe and effective for very young children and the company is submitting a request for its approval to US and international drug regulators.
In a publication published on its website, Moderna said that preliminary data from its 2/3 study showed a “strong neutralizing antibody response” from the 25 micrograms two-dose series of the vaccine in children aged 6 months to almost 2 years. , and children from 2 years to almost 6 years.
Based on these findings, the company said it would submit a request for approval for the two-dose series for children aged 6 months to almost 6 years to the US Food and Drug Administration, the European Medicines Agency and other international regulators in the near future. weeks.
If approved, it would be the first vaccine available in the United States for children under 5 years of age. The Pfizer-BioNTech vaccine is now available in smaller doses for children 5 to 12 years old and in full size for 12 years and older.
The first study of the Pfizer vaccine in children aged 2 to 4 years showed a weaker immune response than in adults, forcing the study to be extended to test the third dose. Results are expected in April.
Some information for this report was provided by the Associated Press, Reuters, and Agence France-Presse.
Moderna says the COVID-19 vaccine is safe, effective for young children
Source link Moderna says the COVID-19 vaccine is safe, effective for young children